Drug intelligence / Profile preview

FIM-001

Development stage: Preclinical
Lead developer: FIMECS
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

FIM-001 is a preclinical, first-in-class proteolysis-targeting chimera (PROTAC) designed to degrade interleukin 1 receptor associated kinase 3 (IRAK3, also known as IRAK-M). Developed by FIMECS, Inc., the drug leverages targeted protein degradation to inhibit IRAK3 function. The primary therapeutic focus is on cancer immunotherapy, with active development for non-small cell lung cancer and pancreatic cancer. By degrading IRAK3—a negative regulator of innate immune signaling—FIM-001 aims to enhance anti-tumor immunity and overcome immune suppression in the tumor microenvironment[1][4].

Other names: IRAK-M protein degrader

Targets

IRAK3

Beyond the preview

Go deeper on FIM-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIM-001.

Explore the full profile